|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 358.33 USD | +1.56% |
|
+6.14% | +9.48% |
| 27/06 | US FDA greenlights Viridian's thyroid eye disease drug | RE |
| 27/06 | US FDA greenlights Viridian's eye disease drug | RE |
| Market Cap | 19TCr 17TCr 16TCr 15TCr 27TCr 18,24300Cr 28TCr 1,87900Cr 73TCr 9,01600Cr 73TCr 71TCr 31,26400Cr | P/E 2026 * |
23.3x | P/E 2027 * | 21.2x |
|---|---|---|---|---|---|
| Enterprise Value | 23TCr 21TCr 19TCr 18TCr 33TCr 22,13300Cr 34TCr 2,27900Cr 88TCr 10,93900Cr 88TCr 86TCr 37,93000Cr | EV / Sales 2026 * |
6.21x | EV / Sales 2027 * | 5.9x |
| Free-Float |
99.78% | Yield 2026 * |
2.81% | Yield 2027 * | 2.97% |
Last Transcript: Amgen Inc.
| 1 day | +1.56% | ||
| 1 week | +6.14% | ||
| Current month | +6.40% | ||
| 1 month | +6.63% | ||
| 3 months | +2.74% | ||
| 6 months | +7.63% | ||
| Current year | +9.48% |
| 1 week | 337.6 |  | 362.27 |
| 1 month | 322.3 | | 362.27 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.44 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
Esteban Santos
COO | Chief Operating Officer | 59 | 25/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/05 | Free | Director | 665 | 0.0001% | ||
| 19/05 | Free | Director | 665 | 0.0001% | ||
| 19/05 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.56% | +6.14% | +29.30% | +60.97% | 19TCr | |
| +7.13% | +9.97% | +55.80% | +160.09% | 1,07700Cr | |
| +3.99% | +11.50% | +67.09% | +55.96% | 61TCr | |
| +4.20% | +17.03% | +38.97% | +91.06% | 45TCr | |
| +0.99% | +4.85% | +28.17% | +23.89% | 33TCr | |
| +1.82% | +8.19% | +40.04% | +27.95% | 29TCr | |
| +0.22% | +6.75% | +31.30% | +42.34% | 29TCr | |
| +0.73% | +8.53% | -27.33% | -39.55% | 21TCr | |
| +3.26% | +3.33% | +15.55% | +68.24% | 16TCr | |
| +2.62% | -3.65% | +0.41% | -33.31% | 14TCr | |
| Average | +2.65% | +6.59% | +27.93% | +45.76% | 37.55TCr | |
| Weighted average by Cap. | +3.80% | +8.37% | +40.23% | +75.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.78TCr 3.31TCr 3.05TCr 2.86TCr 5.36TCr 3,56400Cr 5.47TCr 37TCr 14TCr 1,76100Cr 14TCr 14TCr 6,10800Cr | 3.87TCr 3.4TCr 3.13TCr 2.93TCr 5.5TCr 3,65500Cr 5.61TCr 38TCr 15TCr 1,80700Cr 15TCr 14TCr 6,26400Cr |
| Net income | 826.46Cr 724.64Cr 667.96Cr 625.34Cr 1.17TCr 78TCr 1.2TCr 8.03TCr 3.11TCr 39TCr 3.1TCr 3.04TCr 1,33600Cr | 904.06Cr 792.68Cr 730.67Cr 684.06Cr 1.28TCr 85TCr 1.31TCr 8.78TCr 3.4TCr 42TCr 3.39TCr 3.32TCr 1,46200Cr |
| Net Debt | 4.12TCr 3.62TCr 3.33TCr 3.12TCr 5.85TCr 3,88900Cr 5.97TCr 40TCr 15TCr 1,92200Cr 15TCr 15TCr 6,66600Cr | 3.51TCr 3.08TCr 2.84TCr 2.65TCr 4.98TCr 3,30900Cr 5.08TCr 34TCr 13TCr 1,63600Cr 13TCr 13TCr 5,67200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/26/26 | $358.33 | +1.56% | 36,10,561 |
| 25/26/25 | $352.82 | +0.40% | 23,41,847 |
| 24/26/24 | $351.43 | +1.27% | 23,91,890 |
| 23/26/23 | $347.01 | +0.66% | 23,04,951 |
| 22/26/22 | $344.72 | +2.11% | 25,20,964 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
